<DOC>
	<DOCNO>NCT01426867</DOCNO>
	<brief_summary>The purpose study describe ocular discomfort immediately upon instillation Brinzolamide 1 % /Brimonidine 0.2 % Tartrate Ophthalmic Suspension , Brinzolamide 1 % Ophthalmic Suspension , Brimonidine Tartrate 0.2 % Ophthalmic Solution subject open-angle glaucoma and/or ocular hypertension .</brief_summary>
	<brief_title>A Comfort Study Brinzolamide 1 % / Brimonidine 0.2 % Fixed Combination , Brinzolamide 1 % Brimonidine 0.2 %</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Sign Informed Consent document . Diagnosis openangle glaucoma ocular hypertension Other protocolspecified inclusion criterion may apply . Females childbearing potential pregnant , lactating , use highly effective birth control measure . Severe central vision loss either eye . Any chronic recurrent inflammatory eye disease . Ocular trauma within precede 6 month . Ocular infection ocular inflammation within precede 3 month . Bestcorrected visual acuity score worse 55 letter use Early Treatment Diabetic Retinopathy Study chart . Any intraocular surgery within precede 6 month . Any ocular laser surgery within precede 3 month . History current evidence severe illness condition would make subject , opinion Investigator , unsuitable study . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Open-Angle Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
	<keyword>Intraocular Pressure</keyword>
	<keyword>Brinzolamide</keyword>
	<keyword>Brimonidine</keyword>
</DOC>